[2015-Feb-25] FDA approves new antibacterial drug Avycaz

[2015-Feb-25] FDA approves new antibacterial drug Avycaz

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435629.htm

Avycaz.cdx

Ludo Verbist and Jan Verhaegen, GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae, Antimicrob. Agents Chemother., 1980, 17 (5), pp 807-812

http://dx.doi.org/10.1128/AAC.17.5.807

Ken Coleman, Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors, Curr. Opin. Microbiol., 2011, 14 (5), pp 550-555

http://dx.doi.org/10.1016/j.mib.2011.07.026

Z. Aktaş, C. Kayacan and O. Oncul, In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae, Int. J. Antimicrob. Agents, 2012, 39 (1), pp 86-89

http://dx.doi.org/10.1016/j.ijantimicag.2011.09.012

George G. Zhanel, Christopher D. Lawson, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Philippe R. S. Lagacé-Wiens, Andrew Denisuik, Ethan Rubinstein, Alfred S. Gin, Daryl J. Hoban, Joseph P. Lynch 3rd and James A. Karlowsky, Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination, Drugs, 2013, 73 (2), pp 159-177

http://dx.doi.org//10.1007/s40265-013-0013-7